¼«ËÙÁùºÏ²Ê

Skip to main content
Michael P. Teske
( out of 354 reviews )

Michael P. Teske, MD

Languages spoken: English

Clinical Locations

John A. Moran Eye Center

Salt Lake City
801-581-2352

Midvalley Health Center

Murray
801-581-2955
  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification

    American Board of Ophthalmology
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 354 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 27, 2024
    MORAN EYE CENTER

    Excellent, patient, great bedside manner

    July 26, 2024
    MORAN EYE CENTER

    Attentive, interested, engaged in dialogue with me about procedure and care after. Exhibits trustworthiness and care which come through in his practice! All around someone I trusted my vision to and he came through as expected. Definitely one of the best of the best! Thank you Dr. Teske!

    July 26, 2024
    MORAN EYE CENTER

    Straight talk , pleasant, explained to my level of understanding. Appreciated

    July 20, 2024
    MORAN EYE CENTER

    Dr. Teske provided me with excellent care and instructions. Answered every question I had and explained all procedures. Great experience for me.

    July 20, 2024
    MORAN EYE CENTER

    Dr. Teske is very thorough and his treatment technique is excellent ... I felt no discomfort with the injection.

    July 18, 2024
    MORAN EYE CENTER

    Dr. Teske wasn't there for this visit. Those who filled in for him did a nice job.

    July 05, 2024
    MORAN EYE CENTER

    Fantastic provider.

    June 28, 2024
    MORAN EYE CENTER

    Dr. is a very skilled and knowledgeable physician. I am pleased to have as my physician.

    June 24, 2024
    MORAN EYE CENTER

    He did not make me feel like a new patient. He was warm, friendly, and took the time to explain everything.

  • Michael P. Teske is the Director of Vitreoretinal Diseases and Surgery. Dr. Teske specializes in medical and surgical diseases of the retina and vitreous. His primary surgical interests include retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, retinopathy of prematurity, epiretinal membranes, macular holes and posterior segment trauma.

    Board Certification and Academic Information

    Academic Departments Ophthalmology & Visual Sciences -Primary
    Board Certification
    American Board of Ophthalmology
    National Board of Medical Examiners

    Education history

    Fellowship Retina/Vitreous - Wayne State University, Kresge Eye Institute Fellow
    Ophthalmology - University of ¼«ËÙÁùºÏ²Ê School of Medicine Resident
    Internship Internal Medicine - University of ¼«ËÙÁùºÏ²Ê School of Medicine Intern
    Medicine - University of California - Los Angeles M.D.
    Undergraduate University of Notre Dame B.S.

    Selected Publications

    Journal Article

    1. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NK, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (08/01/2018). Effect of Oral Valproic Acid vs. Placdbo for Vision Loss in Paients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856.
    2. Birch DG, Bernstein PS, Iannacone A, Pennesi ME, Lam BL, Heckenlively J, Csaky K, Hartnett ME, Winthrop KL, Jayasundera T, Hughbanks-Wheaton DK, Warner J, Yang P, Fish GE, Teske MP, Sklaver NL, Erker L, Chegarnov E, Smith T, Wahle A, VanVeldhuisen PC, McCormack J, Lindblad R, Bramer S, Rose S, Zilliox P, Francis PJ, Weleber RG (2018). Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. JAMA Ophthalmol, 136(8), 849-856. ()
    3. Bell JE, Shulman JP, Swan RJ, Teske MP, Bernstein PS (2017). Intravitreal Versus Subretinal Tissue Plasminogen Activator Injection for Submacular Hemorrhage. Ophthalmic Surg Lasers Imaging Retina, 48(1), 26-32. ()